This post was originally published on this site
Advisors to the U.S. Food and Drug Administration had on Tuesday voted overwhelmingly to recommend that the regulator authorize Pfizer (NYSE:PFE) and BioNTech’s vaccine for younger children.
The shot has been authorized for ages 12-15 since May and it was cleared for those aged 16 and above in December last year.
